Table 3. Cardiac (echocardiographic parameters and BNP), functional and end-organ function changes at baseline, 3 months, 6 months and at 1 year in CF-LVAD recipients.
| Variable | Baseline (mean ± SD) | 3 months (mean ± SD) | 6 months (mean ± SD) | 1 year (mean ± SD) | P value |
|---|---|---|---|---|---|
| Cardiac | |||||
| LVEDD (cm) | 7.5±0.9 | 6.2±1.0 | 6.3±1.0 | 6.3±1.1 | Baseline—3 months (<0.001) |
| LVESD (cm) | 6.7±1.1 | 5.3±1.2 | 5.3±1.1 | 5.3±1.3 | Baseline—3 months (<0.001) |
| LVEF (%) | 16.1±4.9 | 29.7±10.7 | 32.3±12.5 | 35.2±12.5 | Baseline—3 months (<0.001); 6–12 months (0.040) |
| BNP (pg/mL)* | 828 [409–1,382] | 304 [145–597] | 223 [109–410] | 192 [103–374] | Baseline—3 months (<0.001) |
| NYHA | 4 | 2.1±0.5 | 1.6±0.5 | 1.4±0.8 | Baseline—3 months (<0.001); 3–6 months (<0.001) |
| Renal | |||||
| BUN (mmol/L) | 8.6±4.2 | 6.1±1.5 | 7.7±6.9 | 7.4±3.3 | Baseline—3 months (<0.001) |
| Creatinine (μmol/L) | 98.9±33.2 | 90.7±21.1 | 102.3±53.1 | 110±49.1 | >0.05 |
| eGFR (mL/min/1.73m2) | 55.5±8.8 | 58.0±4.7 | 56.7±9.1 | 55.7±9.7 | Baseline—3 months (0.050) |
| Liver | |||||
| Total bilirubine (mg/dL) | 25.4±19.9 | 14.3±8.5 | 14.3±6.1 | 16±8.1 | Baseline—3 months (0.001) |
| AST (IU/L)* | 29 [22–35] | 29 [25–37] | 25 [22–33] | 31 [22–35] | >0.05 |
| ALT (IU/L)* | 25 [17–37] | 20 [14–30] | 19 [13–29] | 21 [16–30] | >0.05 |
*, data are presented as median [25th to 75th percentile]. AST, aspartate transaminase; ALT, alanine transaminase; BNP, brain-type natriuretic peptide; BUN, blood urea nitrogen; CF-LVAD, continuous flow left ventricular assist device; eGFR, estimated glomerular filtration rate; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.